Prophylaxis regimens for GVHD: systematic review and meta-analysis (original) (raw)

• Davies JK, Lowdell MW . New advances in acute graft-versus-host disease prophylaxis. Transfus Med 2003; 13: 387–397.
  Article CAS PubMed Google Scholar
• Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406–414.
  Article CAS PubMed Google Scholar
• Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110: 3784–3792.
  Article CAS PubMed PubMed Central Google Scholar
• Lazarus HM, Vogelsang GB, Rowe JM . Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant 1997; 19: 577–600.
  Article CAS PubMed Google Scholar
• Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E . Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000; 96: 2391–2398.
  CAS PubMed Google Scholar
• Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995; 85: 3746–3753.
  CAS PubMed Google Scholar
• Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621–625.
  Article CAS PubMed Google Scholar
• Furlong T, Kiem HP, Appelbaum FR, Carpenter PA, Deeg HJ, Doney K et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008; 14: 531–537.
  Article CAS PubMed PubMed Central Google Scholar
• Bacigalupo A . Management of acute graft-versus-host disease. Br J Haematol 2007; 137: 87–98.
  Article CAS PubMed Google Scholar
• Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 2006. www.cochrane.org.
• Storb R, Martin P, Deeg HJ, Sanders JE, Pepe M, Singer J et al. Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia. Blood 1992; 79: 3091–3092.
  CAS PubMed Google Scholar
• Torres A, Martinez F, Gomez P, Herrera C, Rojas R, Gomez-Villagran JL et al. Cyclosporin A versus methotrexate, followed by rescue with folinic acid as prophylaxis of acute graft-versus-host disease after bone marrow transplantation. Blut 1989; 58: 63–68.
  Article CAS PubMed Google Scholar
• Backman L, Ringdon O, Tollemar J, Lannqvist B . An increased risk of relapse in cyclosporin-treated compared with methotrexate-treated patients: long-term follow-up of a randomized trial. Bone Marrow Transplant 1988; 3: 463–471.
  CAS PubMed Google Scholar
• Atkinson K, Biggs JC, Concannon A, Dodds A, Downs K, Ashby M . A prospective randomised trial of cyclosporin versus methotrexate after HLA-identical sibling marrow transplantation for patients with acute leukemia in first remission: analysis 2.5 years after last patient entry. Aust NZJ Med 1988; 18: 594–599.
  Article CAS Google Scholar
• Ringden O, Backman L, Lönnqvist B, Heimdahl A, Lindholm A, Bolme P et al. A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant 1986; 1: 41–51.
  CAS PubMed Google Scholar
• Irle C, Deeg HJ, Buckner CD, Kennedy M, Clift R, Storb R et al. Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. Leuk Res 1985; 9: 1255–1261.
  Article CAS PubMed Google Scholar
• Kansu E, Gooley T, Flowers ME, Anasetti C, Deeg HJ, Nash RA et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood 2001; 98: 3868–3870.
  Article CAS PubMed Google Scholar
• Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000; 95: 1572–1579.
  CAS PubMed Google Scholar
• Pession A, Locatelli F, Zecca M, Rondelli R, Prete A, Bonetti F et al. Cyclosporine-A as GVHD prophylaxis in allogeneic BMT for childhood acute leukemia. AIEOP-BMT group. Bone Marrow Transplant 1998; 21: S50–S52.
  PubMed Google Scholar
• Storb R, Leisenring W, Anasetti C, Appelbaum FR, Deeg HJ, Doney K et al. Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? Biol Blood Marrow Transplant 1997; 3: 194–201.
  CAS PubMed Google Scholar
• Bacigalupo A, Van Lint MT, Occhini D, Gualandi F, Lamparelli T, Sogno G et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423–1428.
  CAS PubMed Google Scholar
• Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989; 320: 828–834.
  Article CAS PubMed Google Scholar
• Sorror ML, Leisenring W, Deeg HJ, Martin PJ, Storb R . Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 567–568.
  Article PubMed Google Scholar
• Storb R, Leisenring W, Deeg HJ, Anasetti C, Appelbaum F, Bensinger W et al. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. Blood 1994; 83: 2749–2750.
  CAS PubMed Google Scholar
• Ringden O . Decreased transplant-related complications and improved leukemia-free survival in adults receiving methotrexate combined with cyclosporin compared with either agent alone for prevention of graft-versus-host disease. Advisory Committee of the International Bone Marrow Transplant Registry. Transplant Proc 1993; 25: 1241–1242.
  CAS PubMed Google Scholar
• Storb R, Deeg HJ, Pepe M, Doney K, Appelbaum F, Beatty P et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol 1989; 72: 567–572.
  Article CAS PubMed Google Scholar
• Gondo H, Harada M, Taniguchi S, Akashi K, Hayashi S, Teshim T et al. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease. Bone Marrow Transplant 1993; 12: 437–441.
  CAS PubMed Google Scholar
• Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942–2947.
  Article CAS PubMed Google Scholar
• McCann S, Passweg J, Bacigalupo A, Locasciulli A, Locatelli F, Ryan J et al The influence of cyclosporin alone, or cyclosporin and methotrexate, on the incidence of mixed haematopoietic chimaerism following allogeneic sibling bone marrow transplantation for severe aplastic anaemia. Bone Marrow Transplant 2007; 39: 109–114.
  Article CAS PubMed Google Scholar
• Lee KH, Choi SJ, Lee JH, Kim S, Seol M, Lee YS et al. Cyclosporine alone vs cyclosporine plus methotrexate for post-transplant immunosuppression after HLA-identical sibling bone marrow transplantation: a randomized prospective study. Bone Marrow Transplant 2004; 34: 627–636.
  Article CAS PubMed Google Scholar
• Mrsic M, Labar B, Bogdanic V, Nemet D, Pavletic Z, Plavsic F et al. Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1990; 6: 137–141.
  CAS PubMed Google Scholar
• Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.
  Article CAS PubMed Google Scholar
• Zikos P, Van Lint MT, Frassoni F, Lamparelli T, Gualandi F, Occhini D et al. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate. Blood 1998; 91: 3503–3508.
  CAS PubMed Google Scholar
• Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225–1230.
  Article CAS PubMed Google Scholar
• Atkinson K, Biggs J, Concannon A, Dodds A, Young S, Wilson F et al. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy. Aust NZJ Med 1991; 21: 850–856.
  Article CAS Google Scholar
• Storb R, Pepe M, Anasetti C, Appelbaum FR, Beatty P, Doney K et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76: 1037–1045.
  CAS PubMed Google Scholar
• Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 1997; 89: 3880–3887.
  CAS PubMed Google Scholar
• Hiraoka A, Ohashi Y, Okamoto S, Moriyama Y, Nagao T, Kodera Y et al. Japanese FK506 BMT (Bone Marrow Transplantation) Study Group. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 181–185.
  Article CAS PubMed Google Scholar
• Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.
  CAS PubMed Google Scholar
• Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303–2314.
  CAS PubMed Google Scholar
• Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729–1734.
  CAS PubMed Google Scholar
• Ross M, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. Biol Blood Marrow Transplant 1999; 5: 285–291.
  Article CAS PubMed Google Scholar
• Sayer HG, Longton G, Bowden R, Pepe M, Storb R . Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 1994; 84: 1328–1332.
  CAS PubMed Google Scholar
• Horowitz MM, Przepiorka D, Bartels P, Buell DN, Zhang MJ, Fitzsimmons WE et al. Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. Biol Blood Marrow Transplant 1999; 5: 180–186.
  Article CAS PubMed Google Scholar
• Yanada M, Emi N, Naoe T, Sakamaki H, Takahashi S, Hirabayashi N et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplant 2004; 34: 331–337.
  Article CAS PubMed Google Scholar
• Busuttil RW, Lake JR . Role of tacrolimus in the evolution of liver transplantation. Transplantation 2004; 77: S44–S51.
  Article CAS PubMed Google Scholar
• Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg L . Immunoglobulin prophylaxis in hematopoietic stem cell transplantation—systematic review and meta-Analysis. J Clin Oncol 2008 Accepted (in press).
• Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L . Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24: 5207–5215.
  Article CAS PubMed Google Scholar
• Hartman AR, Williams SF, Dillon JJ . Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998; 22: 439–443.
  Article CAS PubMed Google Scholar
• Group Stem Cell Trialists' Collaborative. Allogeneic peripheral blood stem cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074–5087.
  Article Google Scholar
• Bensinger W . Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration. Bone Marrow Transplant 2006; 38: 539–546.
  Article CAS PubMed PubMed Central Google Scholar
• Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005; 36: 757–769.
  Article CAS PubMed Google Scholar
• Nevo S, Enger C, Swan V, Wojno KJ, Fuller AK, Altomonte V et al. Acute bleeding after allogeneic bone marrow transplantation: association with graft versus host disease and effect on survival. Transplantation 1999; 67: 681.
  Article CAS PubMed Google Scholar
• Lazarus HM, Coccia PF, Herzig RH . Incidence of acute graft-versus-host disease with and without methotrexate prophylaxis in bone marrow transplant patients. Blood 1984; 64: 215–220.
  CAS PubMed Google Scholar
• Elfeinbein G, Goedert T, Graham-Pole J . Is prophylaxis against acute graft-versus-host disease necessary if treatment is effective and survival not impared. Proc Am Soc Clin Oncol 1986; 5: 643 (abstract).
• Sullivan KM, Deeg HJ, Sanders J . Hyperacute graft-versus-host disease in patients not given immunosupression after allogeneic marrow transplant. Blood 1986; 67: 1172–1175.
  CAS PubMed Google Scholar
• Bacigalupo A, Oneto R, Lamparelli T, Gualandi F, Bregante S, Raiola AM et al. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant 2001; 28: 1093–1096.
  Article CAS PubMed Google Scholar